Evidence map›Paper›PMID 39850080›Full record

ArticleRSC advances2025

Deciphering allosteric mechanisms in KRAS activation: insights from GTP-induced conformational dynamics and interaction network reorganization.

De-Rui Zhao, Ji-Tong Yang, Meng-Ting Liu, Li-Quan Yang, Peng Sang

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Targeted therapeutic strategies forTranslational lung cancer research · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

De-Rui ZhaoCollege of Agriculture and Biological Science, Dali University Dali 671000 China ylqbioinfo@gmail.com speng431@163.com.ORCID https://orcid.org/0009-0008-2703-4071
Ji-Tong YangCollege of Basic Medical Sciences, Kunming Medical University Kunming 650500 China.
Meng-Ting LiuCollege of Agriculture and Biological Science, Dali University Dali 671000 China ylqbioinfo@gmail.com speng431@163.com.ORCID https://orcid.org/0009-0006-3420-0483
Li-Quan YangCollege of Agriculture and Biological Science, Dali University Dali 671000 China ylqbioinfo@gmail.com speng431@163.com.ORCID https://orcid.org/0000-0002-4958-3345
Peng SangCollege of Agriculture and Biological Science, Dali University Dali 671000 China ylqbioinfo@gmail.com speng431@163.com.ORCID https://orcid.org/0000-0002-8556-2461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conformational dynamics and activation mechanisms of KRAS proteins are of great importance for targeted cancer therapy. However, the detailed molecular mechanics of KRAS activation induced by GTP binding remains unclear. In this study, we systematically investigated how GTP/GDP exchange affects the thermodynamic and kinetic properties of KRAS and explored the activation mechanism using molecular dynamics (MD) simulations, Markov state models (MSMs), and neural relational inference (NRI) models. Our MD simulation results show that GTP binding significantly enhances the conformational flexibility of KRAS, and thus promotes its transition to an active conformation with more open switch I and II regions. MSMs analyses show that KRAS in the GTP-bound state can be transitioned to the active state more efficiently during the simulation than in the GDP-bound state. In addition, NRI model calculations showed that GTP binding enhanced residue-residue interactions within the KRAS protein, especially when the long-range interactions were significantly enhanced. Furthermore, the allosteric signaling pathways from the P-loop to switch I and II as well as the key amino acid sites along the pathways were obtained using a graph-based shortest path analysis. Our results can contribute to a deeper understanding of the mechanism of KRAS allosteric activation and provide a foundation for the development of targeted therapeutic drugs to regulate KRAS activity.

Identifiers

PMID39850080
PMCPMC11755325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.